Brief: Oncolytics Biotech® And Solti Achieve Primary Endpoint In Aware-1 Study
12/04/2021 12:24
April 12 (Reuters) - Oncolytics Biotech Inc ONC.TO :
* ONCOLYTICS BIOTECH® AND SOLTI ACHIEVE PRIMARY ENDPOINT IN
AWARE-1 STUDY
* ONCOLYTICS BIOTECH INC - PELAREOREP ALONE AND WITH
CHECKPOINT
BLOCKADE CONVERTS TUMORS TO PD-L1 POSITIVE CLASSIFICATION
* ONCOLYTICS BIOTECH INC - ONCOLYTICS VALIDATES THAT
PELAREOREP
SIGNIFICANTLY IMPROVES IMMUNOTHERAPIES
* ONCOLYTICS BIOTECH INC - PELAREOREP AND ATEZOLIZUMAB
SYNERGIZE
ANTI-CANCER IMMUNE RESPONSE IN HR+/HER2- BREAST CANCER PATIENTS
Source text for Eikon: ID:nPn7DmMl1a
Further company coverage: ONC.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Files For Mixed Shelf Offering Of Up To $150 Million
Brief: Oncolytics Biotech® Announces Voluntary Delisting From The Toronto Stock Exchange
Advisory: Alert on global oncology breakthroughs tagged to multiple pharma firms withdrawn
Brief: Oncolytics Biotech® Appoints Former Ambrx Executive As Chief Business Officer
Brief: Oncolytics Biotech Appoints Former Ambrx Executive As Chief Business Officer